| HS Code | 764976 |
| Product Name | Compound Phenol Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions |
| Chemical Composition | Phenol (C6H6O) blended with compatible antiseptic/auxiliary agents; proprietary veterinary grade mixture |
| Physical State | Crystalline solid or semisolid mass with a characteristic aromatic odor |
| Solubility | Soluble in water, ethanol, ether, chloroform, glycerol, and fixed or volatile oils |
| Ph Value | Approximately 5.0 to 6.5 in aqueous solution depending upon concentration |
| Mechanism Of Action | Denatures microbial proteins and disrupts cell membrane integrity, leading to cell lysis and death |
| Antimicrobial Spectrum | Bactericidal against many gram-positive and gram-negative bacteria; also active against fungi and certain viruses |
| Indications | Used as a veterinary antiseptic, disinfectant, deodorant, and antipruritic agent |
| Target Species | Cattle, sheep, goats, pigs, poultry, horses, dogs, and cats as per veterinary formulation approval |
| Storage Conditions | Store in tightly closed containers, protected from light, in a cool dry place away from heat sources |
| Shelf Life | Generally 24 to 36 months from manufacture date under recommended storage conditions |
| Dosage Form Compatibility | Formulatable into tablets, injections, capsules, powders, granules, premixes, and solutions with appropriate excipients |
| Molecular Weight | 94.11 g/mol for the phenol component |
| Melting Point | Approximately 40.5°C for the phenol component |
| Boiling Point | Approximately 181.7°C for the phenol component |
As an accredited Compound Phenol Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | Packaged in 25 kg sealed double-lined polyethylene drums, ensuring product stability, safety, and ease of handling for veterinary pharmaceutical manufacturing. |
| Container Loading (20′ FCL) | One 20′ FCL loaded with securely palletized drums of Compound Phenol Veterinary Grade API, ready for pharmaceutical dosage forms. |
| Shipping | Compound Phenol (Veterinary Grade API) ships in sealed, UN-approved drums or containers to prevent leakage and contamination. It is classified as hazardous, requiring proper labeling, documentation, and temperature-controlled transport. Delivery is worldwide via air, sea, or road, complying with international veterinary and chemical safety regulations. |
| Storage | Store in a cool, dry, well-ventilated area, away from direct sunlight, heat, and moisture. Keep in tightly sealed, corrosion-resistant containers, protected from air and incompatibles such as oxidising agents. Avoid storage above 20–25°C to prevent liquefaction or discolouration. Ensure area is secure, clearly labelled, and separated from food, feed, and animals. |
| Shelf Life | Shelf life: 24 months when stored in well-closed containers, protected from light, in a cool, dry place. |
In veterinary tablet manufacturing, Compound Phenol Veterinary Grade API is typically loaded at 2 mg to 50 mg per unit, a range that places content uniformity stress on direct compression unless pre-blending and granulation are correctly specified. Direct compression is viable only when the active is first sieved through a 150 µm stainless steel screen and then pre-blended with lactose monohydrate at a 1:9 mass ratio in a bin blender fitted with an intensifier bar rotating at 6–12 rpm for 15–20 minutes. Without this sequence, low-dose tablet blends can exhibit relative standard deviations greater than 5.0% when tested to USP <905> or Ph. Eur. 2.9.6. Wet granulation remains the preferred route for strengths below 10 mg. A typical formulation uses microcrystalline cellulose PH-102 at 25–40 wt%, lactose monohydrate 200 mesh at 40–60 wt%, crospovidone at 3.0–5.0 wt%, and magnesium stearate at 0.5–1.0 wt%. Contact surfaces are specified as 316L stainless steel or Hastelloy C-22 because phenolic actives can form colored complexes with trace iron during extended wet-massing residence times above 30 minutes.
Compression runs on a rotary press with B-tooling are sustained at precompression force of 4–8 kN and main compression force of 8–25 kN to produce tablet hardness in the range of 50–90 N. Turret speed is normally capped at 40–70 rpm; above this range, dwell-time variation in the compaction zone produces measurable capping and upper-punch sticking when residual granule moisture exceeds 2.5% w/w. In-process testing includes hardness by Ph. Eur. 2.9.8, friability below 1.0% by Ph. Eur. 2.9.7 / USP <1216>, and disintegration under 10 minutes in purified water at 37±2°C by USP <701>. When odor or oxidation is a concern, a hypromellose-based film coating at 3–4% weight gain is applied; coating pan exhaust temperature is held at 40–50°C to avoid melting or sublimation within the phenolic component.
Injectable presentations require dissolution of Compound Phenol Veterinary Grade API in Water for Injections at 0.1–2.0% w/v. The solution pH is adjusted with 0.1 M sodium hydroxide or hydrochloric acid to 4.5–6.5, and tonicity is corrected with sodium chloride to 280–320 mOsm/kg, measured on a freezing point osmometer per USP <785>. Nitrogen sparging at 0.5–1.5 L/min for 10 minutes before final volume adjustment reduces dissolved oxygen; if oxidative browning is observed in stability trials, sodium metabisulfite is included at 0.05–0.2% w/v. The solution is filtered through a 0.22 µm PVDF membrane rather than nylon, because phenolic actives can extract nylon oligomers and raise background absorbance in the finished product. Filter integrity is confirmed by bubble point testing at the membrane manufacturer’s specified pressure, commonly 3.2–3.5 bar for a 0.22 µm PVDF cartridge.
Terminal sterilization by moist heat at 121°C for 15 minutes or an equivalent F0 ≥ 8 minutes is generally applicable, but assay loss of 2–4% is observed when headspace oxygen exceeds 5% v/v. Filling under nitrogen overlay into amber Type II glass vials with bromobutyl rubber stoppers is therefore standard on aseptic lines. Sterilization cycle development follows Ph. Eur. 5.1.1. Release limits include endotoxin below 0.5 EU/mg by Ph. Eur. 2.6.14, particulate matter per Ph. Eur. 2.9.19, and HPLC assay using Ph. Eur. 2.2.29 with an in-house reference standard. Residual solvent levels are controlled under VICH GL18 when organic solvents are used in purification or liquid manufacturing.
Because hard gelatin shells become brittle below 12% w/w moisture and sticky above 16% w/w, capsule production with Compound Phenol Veterinary Grade API must control blend loss on drying to not more than 3.0% w/w by Ph. Eur. 2.2.32. The active is triturated with pregelatinized starch or lactose monohydrate at a 1:5 mass ratio in a low-shear planetary mixer before being combined with the remaining excipients. Dosator-type capsule fillers require plug ejection force between 15 N and 40 N; lower values cause weight variability, while higher values produce laminate plugs and split capsules during closure. Dissolution testing is conducted in 900 mL of pH 1.2 simulated gastric fluid at 50 rpm paddle speed, with a Q value of 75% at 45 minutes, per USP <711> or Ph. Eur. 2.9.3. Hypromellose capsule shells are validated separately because shell opening in pH 4.5 acetate buffer can delay release by 3–5 minutes relative to gelatin.
Oral powder presentations demand particle size control before dry blending. A pin mill or fluidized air jet mill reduces the API to D90 ≤ 150 µm; nitrogen-cooled jet milling is used when the mill outlet temperature would otherwise exceed 45°C, because phenolic materials can soften and fuse on classifier surfaces. A representative sachet composition uses 5–10 wt% Compound Phenol Veterinary Grade API in anhydrous dextrose with 0.5–1.0 wt% colloidal silicon dioxide. The milled active is blended in a ribbon blender at 15–25 rpm for 15–20 minutes; fill weight variation for unit-dose sachets remains within ±5% when tested to Ph. Eur. 2.9.5. Sachet laminate is specified with an oxygen transmission rate below 1.0 cm³/(m²·24 h·bar) to limit oxidative discoloration during warehouse storage. Reconstitution testing in 250 mL of potable water at 20±5°C is included at release to ensure complete dispersion within 60 seconds; this is a process-specific test rather than a pharmacopoeial monographed method.
Granulation scale-up changes binder distribution more than any other variable. In a high-shear mixer of 600 L working volume, binder viscosity at 25°C should be maintained between 10 mPa·s and 25 mPa·s; above 25 mPa·s, the spray pattern widens and uneven binder distribution generates coarse agglomerates larger than 2.0 mm and increases granule bulk density variation. Povidone K30 or pregelatinized starch is used at 3.0–6.0% w/w of dry formulation, sprayed at 0.8–1.5 kg/min; wet massing time is limited to 2–5 minutes after spraying ends. The endpoint is determined by impeller power consumption rather than elapsed time alone, because phenolic actives can alter liquid bridge viscosity under extended wet massing.
Drying in a fluid bed with inlet air at 55–65°C keeps product temperature below 45°C, a limit selected to avoid softening or sublimation of the API. Final loss on drying is controlled to 1.5–2.5% w/w by Ph. Eur. 2.2.32, and dry granules are screened through a 1000 µm sieve before final blending. If the granulation is to be compressed, crospovidone and magnesium stearate are added post-screen at 3.0–5.0 wt% and 0.5–1.0 wt%, respectively. Granule flow following this process typically shows Hausner ratios below 1.25 and Carr indices below 20, measured by USP <1174> or Ph. Eur. 2.9.36.
| Dosage presentation | Control variable | Validated operating range | Method or standard |
|---|---|---|---|
| Tablet | Compression force | 8–25 kN | Ph. Eur. 2.9.8 |
| Injectable | Osmolality | 280–320 mOsm/kg | USP <785> |
| Capsule | Blend loss on drying | ≤3.0% w/w | Ph. Eur. 2.2.32 |
| Oral powder | Sachet fill weight variation | ±5% | Ph. Eur. 2.9.5 |
| Granules | Final loss on drying | 1.5–2.5% w/w | Ph. Eur. 2.2.32 |
| Premix | Mixer distribution CV | ≤5.0% | 21 CFR 225 |
| Solution | pH | 4.5–6.5 | USP <791> |
For medicated premix production, stepwise dilution remains the most reproducible method. Compound Phenol Veterinary Grade API is first combined with calcium carbonate, wheat middlings, or rice hulls at a 1:10 mass ratio in a pilot blender; this intermediate premix is then introduced into a double-shaft paddle mixer or ribbon blender operating at 20–25 rpm for 10–20 minutes. Mixer validation under 21 CFR 225 requires active drug distribution testing across 10 sampling points, with a coefficient of variation not exceeding 5.0% for the target inclusion rate. Target inclusion rates in final feed typically range from 0.5 g/kg to 10 g/kg, depending on species and veterinary indication; batch size adjustments require re-validation rather than linear extrapolation.
Carrier moisture is controlled below 12% w/w because higher moisture promotes phenolic oxidation and caking in multi-wall paper bags. Mineral oil at 0.5–1.0% w/w may be added to reduce dusting, but the total oil load is kept below 2.0% w/w to avoid sticky bridges in the mixer and cross-contamination in downstream feed bins. Premixes are stored at 25°C/60% RH; accelerated stability samples at 40°C/75% RH are placed for 3–6 months to detect packaging failure before commercial release. Sampling plans follow the square root of the lot size plus one, a standard veterinary drug sampling approach consistent with current Good Manufacturing Practice for medicated feeds under 21 CFR 225.
Chlorinated drinking water introduces an oxidative stress variable in solution presentations. Municipal water with free chlorine residuals above 1.0 mg/L can halogenate phenolic APIs to form chlorophenols, reducing assay and producing off-odor. Finished drench solutions are therefore prepared with dechlorinated or purified water; when source water must be used, sodium thiosulfate is added at 1.0–2.0 mg/L and mixed for 5–10 minutes before API addition. Compound Phenol Veterinary Grade API is diluted to 10–100 mg/L in high-density polyethylene or stainless steel proportioner tanks. In-line dosing pumps are calibrated to maintain flow accuracy within ±5% at the target delivery rate.
Solution pH is held at 4.5–6.5; below 4.0, the unionized phenolic fraction increases and may precipitate in cold water at 4–8°C, while above 8.0 phenolate formation changes partitioning and can accelerate color development. Under continuous aeration in livestock barns, the working solution should be consumed or replaced within 24–48 hours at 25°C, and within 12–24 hours when ambient temperature exceeds 30°C. Release controls include pH by USP <791>, clarity, and HPLC assay using Ph. Eur. 2.2.29. Published stability data for this specific veterinary drinking water configuration are limited beyond these operational windows, so site-specific holding time studies are required before field use.
Competitive Compound Phenol Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8615365186327 or mail to admin@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8615365186327
Email: admin@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
Compound Phenol Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is supplied as purified phenol, C6H6O, CAS 108-95-2, molecular weight 94.11 g/mol. The product is released under the model designation CP-VG-API; each batch carries a six-digit lot code, specification revision, and manufacturer’s dossier reference on the certificate of analysis. The material differs from technical-grade phenol by pharmacopoeial release criteria aligned with Ph. Eur. 0629 and by additional controls for related substances, residue on ignition, residual solvents, and microbial quality. Phenol is a low-melting crystalline solid with a solidification point not less than 40.0 °C, water solubility of approximately 8.3 g/100 mL at 20 °C, and pKa 9.95 at 25 °C. These physicochemical boundaries dominate processing decisions across all seven dosage-form claims and separate the API from non-compendial phenol used in resin and chemical intermediate streams.
Substitution of non-pharmacopoeial phenol in injections is prevented by three measurable boundaries: iron-catalysed colour formation, uncontrolled volatile impurity load, and absence of endotoxin data. Technical-grade phenol obtained from cumene-based synthetic streams may contain traces of carbonyl compounds, cresolic impurities, and substituted phenols that react during terminal sterilisation. The API grade is controlled for a maximum non-parent impurity profile and is qualified for water-based systems through a limit of endotoxins, assessed by Ph. Eur. 2.6.14 when the customer designates parenteral use. For dissolution into Water for Injections, conductivity below 1.3 µS/cm at 25 °C, nitrogen overlay, and closed 316L stainless-steel vessels are specified because oxygen ingress accelerates oxidative discoloration of phenolate species. Pre-filtration through a 0.22 µm membrane is performed after pH adjustment, provided the solution temperature remains below 25 °C to reduce loss of active compound through volatilisation. Published data for phenol-specific sterile filtration loading is limited; filter compatibility studies are therefore required for batch-specific production runs exceeding 50 L.
In aqueous injectable processing, the vessel is closed and fitted with a condenser because phenol volatilises from an open surface at process temperatures. The pH is maintained between 5.0 and 6.0 for maximum chemical stability and antimicrobial activity. Above pH 8.5, a larger fraction of phenolate ion forms, which accelerates oxidation and increases discoloration in the presence of residual oxygen. Stainless-steel 316L or glass-lined equipment is used; copper and unlined carbon steel are avoided because surface oxides catalyse colour formation. If steam sterilisation is used, headspace is minimised to 2% of nominal fill volume to limit partitioning of phenol into the vapour phase.
Tablet and capsule manufacturing with this API requires strict heat management because the melting point is only 40.0 °C. In direct compression, phenol crystals are milled to a D90 below 150 µm in a cooled pin mill; frictional heat at the compression stations of rotary tablet presses can soften residual coarse crystals, producing edge chipping and picking when the punch surface reaches approximately 35 °C. Granulation is conducted as wet granulation with a non-aqueous binder or dry granulation with jacketed roller compactors; high-shear granulation bowl temperature is maintained below 30 °C by reduced impeller speed and chilled jacket fluid. Capsule filling is feasible as powder-filled hard capsules when the phenol is pre-adsorbed onto a suitable carrier and the blend moisture is kept below 0.5% loss on drying. Melt-filled hard capsules require a jacketed hopper at 45–50 °C and immediate banding or sealing to control odour and dimensional stability. Aqueous granulation with more than 4% w/w water may dissolve phenol crystals and create sticky agglomerates; if aqueous granulation is unavoidable, the binder solution is cooled below 15 °C and added over short intervals. Published data for aqueous granulation with pure phenol is limited; rheological characterisation of the wet mass is therefore required.
For dry presentations, the primary technical risk is non-uniform distribution of a low-dose active ingredient in feed premixes and powders. The API is incorporated using a two-step geometric dilution; carriers with high surface area reduce segregation during transfer. A 500 µm conical or oscillating sieve is placed after final blending to break spheroidal agglomerates. Batch release uses stratified sampling at 10 locations, with acceptance for blend uniformity set at relative standard deviation not more than 5.0% by weight unless the finished product monograph or VICH GL2 requires tighter limits. For premix operations, ribbon blenders with an intensifier bar and total fill level of 60–70% of gross volume are used; extended mixing beyond 20 minutes may generate electrostatic charge and particle segregation in low-humidity environments. Packaging in aluminium foil laminate with desiccant is required above 60% RH ambient storage; the bulk product is not released if visual surface dampening is observed before the final sampling interval.
Solutions of this API are prepared by adding molten or flaked phenol to a portion of the final aqueous vehicle under turbulent agitation. The dissolution vessel is closed and fitted with a condenser because phenol volatilises from an open surface at process temperatures. The pH is maintained between 5.0 and 6.0 for maximum chemical stability and antimicrobial activity; above pH 8.5, a larger fraction of phenolate ion forms, which accelerates oxidation and increases discoloration in the presence of residual oxygen. Stainless-steel 316L or glass-lined equipment is used; copper and unlined carbon steel are avoided because surface oxides catalyse colour formation. For injectable solutions, the final product is filled under nitrogen and terminally sterilised in closed containers; if steam sterilisation is used, headspace is minimised to 2% of nominal fill volume to limit partitioning of phenol into the vapour phase.
The baseline Ph. Eur. 0629 assay of 99.0–100.5% on anhydrous basis is insufficient alone for injectable and melt-filled capsule applications. Residual water must be controlled to a lower internal release limit because free water liquefies the crystalline mass near the melting point and can produce localised dosing error. For capsule and injection grades, the certificate of analysis should report water content and residual solvents by headspace gas chromatography under ICH Q3C. Class 2 solvents are not accepted above the option 1 limit, and class 3 solvents are controlled to a total daily exposure consistent with the highest intended veterinary dose. If the product is to be used in aqueous injectable formulations, the absence of visible particles is checked after dissolution at 50 mg/mL and filtration through a 0.45 µm test membrane; published data for this specific configuration is limited when the formulation contains non-ionic surfactants, so compatibility studies are required.
The release profile for CP-VG-API is designed as a single specification that remains valid for tablet, capsule, injection, powder, granule, premix, and solution applications. Compendial minimums are supplemented by internal process controls where dosage-form qualification demands tighter limits. The table lists release targets; some values are internal controls stricter than the compendial minimum.
| Parameter | Requirement / release target | Reference method |
|---|---|---|
| Appearance | Colourless or faintly pink crystalline mass, free from dark particulates | Ph. Eur. 0629 |
| Assay, anhydrous basis | 99.0–100.5% m/m | Ph. Eur. 0629 |
| Solidification point | Not less than 40.0 °C | Ph. Eur. 2.2.14 |
| Water content | Not more than 1.0% for oral dry forms; not more than 0.5% for capsule/injection qualification | Internal release control |
| Related substances | Total unspecified impurities not more than 0.5% area by GC unless stricter dossier limit applies | Ph. Eur. 0629 |
| Residue on ignition | Not more than 0.1% | Ph. Eur. 2.4.16 |
| Bacterial endotoxins | Not more than 0.25 EU/mg for injectable claim | Ph. Eur. 2.6.14 |
| Residual solvents | ICH Q3C option 1; Class 2 below 50% of option 1 limit | Ph. Eur. 2.4.24 |
Three physical forms are available under the CP-VG-API release model: crystalline medium-grade for dissolution and injectable compounding, milled grade with D90 below 150 µm for direct compression and capsule powder filling, and low-dust prilled or flaked grade for premix and powder handling. The particle-size distribution is reported by laser diffraction using Ph. Eur. 2.9.31. Crystalline material reduces solvent wetting time in aqueous vehicles but is more prone to bridging in hoppers. Milled material improves blend uniformity but increases surface area, which can accelerate oxidative discoloration if storage humidity is not controlled. The low-dust grade is preferred where containment and operator exposure are dominant; phenol has an occupational exposure limit of 5 ppm as an 8-hour TWA under OSHA/NIOSH guidance. For each physical form, residual particles above 1.0 mm are removed by sieving.
The aqueous degradation chemistry is pH-dependent. At pH 7.4, less than 1% of the phenol is ionised; at pH 9.95, 50% is ionised. The un-ionised molecule is considered the primary antimicrobial form, which imposes a pH below 6.0 for formulations relying on preservative or active antimicrobial function. Under oxidative conditions, phenol forms ring-hydroxylated species such as catechol and hydroquinone, followed by quinoid chromophores. The resulting discoloration is not merely aesthetic; it indicates loss of parent drug and potential formation of dimeric species. Nitrogen overlay and antioxidant-free formulation are therefore used unless interaction studies demonstrate compatibility with a specific antioxidant. For injectable aqueous systems, the oxygen headspace is maintained at or below 2% v/v before sealing, and the finished solution is protected from light where the dossier identifies photodegradation. Stability-indicating assay at 270 nm is used as the routine release wavelength because phenol exhibits strong absorbance in that region.
The narrow processing window around the melting point is operationally significant. At a handling temperature of 25 °C, crystalline phenol remains free-flowing; at 35 °C, surface softening can begin if residual water is high. For milling, jacketed mills are set to 10–15 °C to dissipate frictional heat. For tablet compression, punch temperature is mapped with infrared sensors; if the punch face exceeds 35 °C for more than 5 minutes, the batch is stopped and the press speed is reduced by 20% before restarting. These conditions are operational starting points; batch-specific thermal mapping is required because press geometry and dwell time alter heat accumulation. In capsule filling, powder blends are held in hoppers with air purging at maximum 40% RH; higher humidity raises moisture content above 0.5% and causes sticking in the dosing disc.
Cleaning and changeover are controlled because phenol is volatile and odorous. Surface residues are monitored by swab sampling and high-performance liquid chromatography; the limit of quantification is not greater than 0.1 µg/mL. Equipment washed with hot water above 50 °C can generate phenol vapour that recondenses in ventilation filters; cleaning is therefore performed with cold aqueous detergent followed by ethanol rinse before drying. Dedicated or closed systems are preferred for the milled grade to reduce operator exposure and cross-contamination. These controls are part of plant-specific procedures and are not guaranteed by chemical composition alone.
| Dosage form | Critical processing boundary | Control method / equipment |
|---|---|---|
| Tablets | Punch face ≤ 35 °C; D90 ≤ 150 µm | Cooled pin mill, cooled rotary tablet press |
| Capsules | Blend moisture ≤ 0.5%; melt-fill at 45–50 °C if liquid-filled | Jacketed hopper, banding or sealing station |
| Injections | pH 5.0–6.0; WFI conductivity < 1.3 µS/cm at 25 °C; headspace ≤ 2% | Closed 316L vessel, nitrogen overlay, 0.22 µm filtration |
| Powders/granules | Sieve aperture 500 µm; blend RSD ≤ 5.0% | Oscillating sieve, V-blender or ribbon blender |
| Premix | Packaging at ≤ 60% RH; stratified sampling at 10 locations | Aluminium foil laminate with desiccant, ribbon blender |
| Solutions | Dissolution below 25 °C; closed vessel to control volatilisation | Condenser-equipped 316L vessel |
The distinction between this veterinary API and technical-grade phenol is not solely a purity statement; it is a control of impurities that impact finished-product stability. Industrial phenol from cumene oxidation may contain residual ketones, dibenzofuran, and colour-forming precursors that are acceptable in resin synthesis but unacceptable in aqueous pharmaceutical systems. The API grade is also differentiated from chlorocresol and thymol by its physical-chemical profile. Unsubstituted phenol has greater water solubility and higher headspace mobility than chlorocresol; consequently, rubber closure uptake and headspace losses are more relevant during terminal sterilisation. Compared with cresol isomers, unsubstituted phenol has a lower boiling point and fewer methyl-substituted impurities; the solidification point specification therefore serves as a rapid identity and purity indicator. Compared with hexachlorophene, phenol lacks the chlorinated diphenyl ether structure and therefore does not carry the same dioxin-related impurity concerns; however, it also exhibits a narrower antimicrobial spectrum at neutral pH. These differences determine use level, packaging, and process design rather than implying universal superiority.
Operational boundaries are explicit. The material is incompatible with strong oxidising agents, hypochlorite-based sanitizers, and iron salts due to exothermic or colour-forming reactions. Storage above 30 °C in opened containers leads to sublimation and surface fusion; containers should be reclosed under nitrogen and stored in a ventilated, temperature-mapped area. The API is not intended for direct use as a disinfectant concentrate; dilution and finishing steps are performed by licensed veterinary pharmaceutical manufacturers. Container-closure studies are required for each final formulation because phenolic actives interact with rubber and plastic primary packaging components.
